Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer’s-related psychosis during the ...

Bristol Myers Squibb CEO Chris Boerner described Cobenfy, a new drug to treat schizophrenia and may also help with bipolar ...

Bristol Myers Squibb Co. said its new schizophrenia drug is off to a better start than similar recently launched treatments, ...

The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction ...

Medicare has announced 15 new drugs up for price negotiations, set to begin in the next several months with top drugmakers, ...

On Friday, the U.S. Department of Health and Human Services (HHS) unveiled the selection of 15 additional drugs covered under ...

The Biden administration has announced the next 15 drugs chosen for Medicare negotiation, marking one of its final acts ...

Arsenal Biosciences, Inc., a clinical-stage programmable cell therapy company, announced Monday that drug maker Bristol-Myers Squibb ...

The talks around drugs including Novo Nordisk's Wegovy, GSK's Trelegy Ellipta, and Pfizer's Xtandi will set Medicare prices ...

The FDA has approved Cobenfy, a new drug to treat people with schizophrenia that comes with fewer side effects.

The US plans to slash the price it pays for the Novo Nordisk A/S blockbusters Ozempic and Wegovy, the latest drugs to be ...

Bristol Myers (BMY) new psychiatric drug Cobenfy is effective in treating schizophrenia without “the serious side effects’ of other older ...